Editor’s replyBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c5390 (Published 29 September 2010) Cite this as: BMJ 2010;341:c5390
- Fiona Godlee, editor1
- 1BMJ, London WC1H 9JR, UK
On the face of it, Keegan makes an interesting comparison.1 But on closer inspection the flaws in his logic are evident, to me at least.
Rosiglitazone is legal and non-addictive, and its production and supply are in the hands of one manufacturer. So too is most of the evidence of its benefits and harms. It was …